Beigene Ltd (BGNE)

$221.14

+2.17

(+0.99%)▲

Live

Performance

  • $217.33
    $221.74
    $221.14
    downward going graph

    1.73%

    Downside

    Day's Volatility :1.99%

    Upside

    0.27%

    downward going graph
  • $126.97
    $248.16
    $221.14
    downward going graph

    42.58%

    Downside

    52 Weeks Volatility :48.84%

    Upside

    10.89%

    downward going graph

Returns

PeriodBeigene LtdSector (Health Care)Index (Russel 2000)
3 Months
36.07%
3.6%
0.0%
6 Months
67.23%
10.2%
0.0%
1 Year
29.78%
19.6%
0.0%
3 Years
-41.65%
16.8%
-23.0%

Highlights

Market Capitalization
23.1B
Book Value
$31.73
Earnings Per Share (EPS)
-4.93
PEG Ratio
0.0
Wall Street Target Price
274.6
Profit Margin
-16.91%
Operating Margin TTM
-11.53%
Return On Assets TTM
-9.69%
Return On Equity TTM
-14.62%
Revenue TTM
3.1B
Revenue Per Share TTM
29.65
Quarterly Revenue Growth YOY
56.10000000000001%
Gross Profit TTM
-511.1M
EBITDA
-796.0M
Diluted Eps TTM
-4.93
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-5.56
EPS Estimate Next Year
-1.27
EPS Estimate Current Quarter
-2.15
EPS Estimate Next Quarter
-2.17

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Beigene Ltd(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 24.17%

Current $221.14
Target $274.60

Company Financials

FY18Y/Y Change
Revenue
198.2M
↓ 16.85%
Net Income
-673.8M
↑ 623.67%
Net Profit Margin
-339.91%
↓ 300.85%
FY19Y/Y Change
Revenue
428.2M
↑ 116.03%
Net Income
-950.6M
↑ 41.08%
Net Profit Margin
-221.99%
↑ 117.92%
FY20Y/Y Change
Revenue
308.9M
↓ 27.87%
Net Income
-1.6B
↑ 68.37%
Net Profit Margin
-518.18%
↓ 296.19%
FY21Y/Y Change
Revenue
1.2B
↑ 280.83%
Net Income
-1.4B
↓ 11.69%
Net Profit Margin
-120.15%
↑ 398.03%
FY22Y/Y Change
Revenue
1.4B
↑ 20.37%
Net Income
-2.0B
↑ 41.78%
Net Profit Margin
-141.52%
↓ 21.37%
FY23Y/Y Change
Revenue
2.5B
↑ 73.65%
Net Income
-881.7M
↓ 56.0%
Net Profit Margin
-35.86%
↑ 105.66%
Q1 FY23Q/Q Change
Revenue
447.8M
↑ 17.81%
Net Income
-348.4M
↓ 21.76%
Net Profit Margin
-77.81%
↑ 39.35%
Q2 FY23Q/Q Change
Revenue
595.3M
↑ 32.93%
Net Income
-381.1M
↑ 9.39%
Net Profit Margin
-64.03%
↑ 13.78%
Q3 FY23Q/Q Change
Revenue
781.3M
↑ 31.25%
Net Income
215.4M
↓ 156.52%
Net Profit Margin
27.57%
↑ 91.6%
Q4 FY23Q/Q Change
Revenue
634.4M
↓ 18.8%
Net Income
-367.6M
↓ 270.63%
Net Profit Margin
-57.94%
↓ 85.51%
Q1 FY24Q/Q Change
Revenue
751.7M
↑ 18.48%
Net Income
-251.2M
↓ 31.67%
Net Profit Margin
-33.41%
↑ 24.53%
Q2 FY24Q/Q Change
Revenue
929.2M
↑ 23.62%
Net Income
-120.4M
↓ 52.06%
Net Profit Margin
-12.96%
↑ 20.45%
FY18Y/Y Change
Total Assets
2.2B
↑ 114.98%
Total Liabilities
496.0M
↑ 36.93%
FY19Y/Y Change
Total Assets
1.6B
↓ 28.33%
Total Liabilities
633.9M
↑ 27.8%
FY20Y/Y Change
Total Assets
5.6B
↑ 247.38%
Total Liabilities
1.7B
↑ 173.14%
FY21Y/Y Change
Total Assets
8.6B
↑ 54.37%
Total Liabilities
2.4B
↑ 38.78%
FY22Y/Y Change
Total Assets
6.4B
↓ 26.22%
Total Liabilities
2.0B
↓ 16.94%
FY23Y/Y Change
Total Assets
5.8B
↓ 9.0%
Total Liabilities
2.2B
↑ 11.91%
Q1 FY23Q/Q Change
Total Assets
6.0B
↓ 6.62%
Total Liabilities
1.8B
↓ 9.84%
Q2 FY23Q/Q Change
Total Assets
5.7B
↓ 3.83%
Total Liabilities
1.9B
↑ 7.26%
Q3 FY23Q/Q Change
Total Assets
5.5B
↓ 3.56%
Total Liabilities
1.8B
↓ 8.73%
Q4 FY23Q/Q Change
Total Assets
5.8B
↑ 5.08%
Total Liabilities
2.2B
↑ 26.8%
Q1 FY24Q/Q Change
Total Assets
5.7B
↓ 2.37%
Total Liabilities
2.3B
↑ 1.82%
Q2 FY24Q/Q Change
Total Assets
5.7B
↑ 0.79%
Total Liabilities
2.3B
↑ 1.74%
FY18Y/Y Change
Operating Cash Flow
-547.7M
↓ 4395.15%
Investing Cash Flow
-637.6M
↑ 78.94%
Financing Cash Flow
1.7B
↑ 244.76%
FY19Y/Y Change
Operating Cash Flow
-750.3M
↑ 36.98%
Investing Cash Flow
554.2M
↓ 186.91%
Financing Cash Flow
85.7M
↓ 94.93%
FY20Y/Y Change
Operating Cash Flow
-1.3B
↑ 71.07%
Investing Cash Flow
-3.2B
↓ 671.74%
Financing Cash Flow
5.2B
↑ 5972.39%
FY21Y/Y Change
Operating Cash Flow
-1.3B
↑ 1.19%
Investing Cash Flow
640.7M
↓ 120.22%
Financing Cash Flow
3.6B
↓ 30.1%
FY22Y/Y Change
Operating Cash Flow
-1.5B
↑ 15.24%
Investing Cash Flow
1.1B
↑ 68.13%
Financing Cash Flow
-19.0M
↓ 100.52%
Q1 FY23Q/Q Change
Operating Cash Flow
-563.8M
↑ 77.18%
Investing Cash Flow
67.8M
↑ 75.94%
Financing Cash Flow
-19.9M
↓ 82.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-293.9M
↓ 47.87%
Investing Cash Flow
67.8M
↑ 0.0%
Financing Cash Flow
166.1M
↓ 935.92%
Q3 FY23Q/Q Change
Operating Cash Flow
-78.2M
↓ 73.41%
Investing Cash Flow
-186.3M
↓ 374.74%
Financing Cash Flow
-76.8M
↓ 146.23%

Technicals Summary

Sell

Neutral

Buy

Beigene Ltd is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Beigene Ltd
Beigene Ltd
8.77%
67.23%
29.78%
-41.65%
64.64%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Beigene Ltd
Beigene Ltd
NA
NA
0.0
-5.56
-0.15
-0.1
NA
31.73
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Beigene Ltd
Beigene Ltd
Buy
$23.1B
64.64%
NA
-16.91%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Beigene Ltd

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 634.40M → 929.16M (in $), with an average increase of 17.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -367.55M → -120.40M (in $), with an average increase of 77.5% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 50.4%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 86.5%

Institutional Holdings

  • Baker Bros Advisors LP

    9.95%

  • Capital Research & Mgmt Co - Division 3

    6.60%

  • Hillhouse Capital Advisors, Ltd.

    4.88%

  • PRIMECAP Management Company

    4.70%

  • Baillie Gifford & Co Limited.

    3.47%

  • Temasek Holdings Ltd.

    2.84%

Corporate Announcements

  • Beigene Ltd Earnings

    Beigene Ltd’s price-to-earnings ratio stands at None

    Read More

Company Information

BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.

Organization
Beigene Ltd
Employees
10000
CEO
Mr. John V. Oyler
Industry
Health Technology

Discover More

FAQs